BI 2536

Generic Name: BI 2536

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₂₈H_₃₉N_₇O_₃

CAS Number: 755038-02-9

Unique Ingredient Identifier: 4LJG22T9C6

Background: BI 2536 is under investigation in clinical trial NCT00376623 (Efficacy and Safety of BI 2536 in Advanced or Metastatic Non Small Cell Lung Cancer).

Associated Conditions: -

Associated Therapies: -

Clinical Trials

PLK1 overexpression suppresses homologous recombination and confers cellular sensitivity to PARP inhibitors

PLK1 overexpression correlates with HRD in various cancers, enhancing sensitivity to PARP inhibitors. Cell experiments confirm PLK1 suppresses HR, increasing PARP inhibitor sensitivity, dependent on PLK1's kinase activity. Clinical ovarian cancer samples show higher PLK1 levels predict greater PARP inhibitor sensitivity.

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy